US congressional inquiry on Ranbaxy drugs has broad reach
This article was originally published in Scrip
Executive Summary
US lawmakers investigating allegations of possible fraud involving Ranbaxy's generic drugs have asked the FDAto turn over an exhaustive list of documents for all of the company's approved medicines. The documents include inspection reports of Ranbaxy, its active pharmaceutical ingredient suppliers and laboratories that performed bioequivalence testing for the firm's applications.